Genprex, Inc. Aktie News

Die Zusammenarbeit ermöglicht Genprex die Beschleunigung der Herstellprozesse für IND-fördernde präklinische Studien und zukünftige klinische Prüfungen AUSTIN, Texas, 18. Aug. 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" oder das "Unternehmen") (NASDAQ: GNPX), ein im klinischen Stadium befindliches Gentherapie-Unternehmen mit Fokus auf die Entwicklung lebensverändernder Therapien für Patienten...

Die Zusammenarbeit fördert biomarkergetriebene Patientenselektion und Präzisionsmedizin in der Onkologie. Validierungsstudien zielen darauf ab, die Kriterien zur Patientenselektion für klinische Studien zu optimieren. AUSTIN, Texas, 3. Aug. 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" oder das "Unternehmen") (NASDAQ: GNPX), ein im klinischen Stadium befindliches Gentherapie-Unternehmen, das le...

Patent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq® AUSTIN, Texas, June 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that The Canadian Intellectual Property Office (C...

The BIO International Convention Brings Together More Than 20,000 Biotech Industry Leaders From Around The World AUSTIN, Texas, June 17, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its team will be attending and parti...

Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine AUSTIN, Texas, May 26, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy com...

Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four Weeks AUSTIN, Texas, May 14, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical da...

Strengthens Patent Estate and Expands Protection in Another Target Market AUSTIN, Texas, April 30, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that The Israel Patent Office (ILPO) has granted Genprex a patent covering the ...

Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four Weeks AUSTIN, Texas, April 28, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present positive preclinic...